Show simple item record

dc.contributor.authorRotunno, M
dc.contributor.authorSun, X
dc.contributor.authorFigueroa, J
dc.contributor.authorSherman, ME
dc.contributor.authorGarcia-Closas, M
dc.contributor.authorMeltzer, P
dc.contributor.authorWilliams, T
dc.contributor.authorSchneider, SS
dc.contributor.authorJerry, DJ
dc.contributor.authorYang, XR
dc.contributor.authorTroester, MA
dc.date.accessioned2018-08-03T13:10:52Z
dc.date.issued2014-07-08
dc.identifier.citationBreast cancer research : BCR, 2014, 16 (4), pp. R74 - ?
dc.identifier.issn1465-5411
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2260
dc.identifier.eissn1465-542X
dc.identifier.doi10.1186/bcr3689
dc.description.abstractINTRODUCTION: Relationships of parity with breast cancer risk are complex. Parity is associated with decreased risk of postmenopausal hormone receptor-positive breast tumors, but may increase risk for basal-like breast cancers and early-onset tumors. Characterizing parity-related gene expression patterns in normal breast and breast tumor tissues may improve understanding of the biological mechanisms underlying this complex pattern of risk. METHODS: We developed a parity signature by analyzing microRNA microarray data from 130 reduction mammoplasty (RM) patients (54 nulliparous and 76 parous). This parity signature, together with published parity signatures, was evaluated in gene expression data from 150 paired tumors and adjacent benign breast tissues from the Polish Breast Cancer Study, both overall and by tumor estrogen receptor (ER) status. RESULTS: We identified 251 genes significantly upregulated by parity status in RM patients (parous versus nulliparous; false discovery rate = 0.008), including genes in immune, inflammation and wound response pathways. This parity signature was significantly enriched in normal and tumor tissues of parous breast cancer patients, specifically in ER-positive tumors. CONCLUSIONS: Our data corroborate epidemiologic data, suggesting that the etiology and pathogenesis of breast cancers vary by ER status, which may have implications for developing prevention strategies for these tumors.
dc.formatElectronic
dc.format.extentR74 - ?
dc.languageeng
dc.language.isoeng
dc.publisherBMC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectReceptors, Estrogen
dc.subjectCluster Analysis
dc.subjectOdds Ratio
dc.subjectRisk Factors
dc.subjectCase-Control Studies
dc.subjectGene Expression Profiling
dc.subjectParity
dc.subjectPregnancy
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectYoung Adult
dc.subjectTranscriptome
dc.titleParity-related molecular signatures and breast cancer subtypes by estrogen receptor status.
dc.typeJournal Article
dcterms.dateAccepted2014-06-25
rioxxterms.versionofrecord10.1186/bcr3689
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2014-07-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBreast cancer research : BCR
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Epidemiology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Epidemiology
pubs.publication-statusPublished
pubs.volume16
pubs.embargo.termsNot known
icr.researchteamMolecular Epidemiology
dc.contributor.icrauthorGarcia-Closas, Montserrat


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0